STAT+: Radiopharma companies merge after one receives surprise FDA rejection — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Telix Pharmaceuticals will acquire all shares of privately held ITM Isotope Technologies Munich SE in a deal worth at least $1.65 billion.
- Telix could pay an additional $700 million to ITM shareholders if ITM's lead drug meets stated regulatory and sales goals.
- Novartis currently dominates the radiopharmaceutical field, which delivers radioactive isotopes directly to cancer cells.
- Novartis launched two radiopharmaceutical treatments in 2018 and 2022, moves the source credits with supercharging the sector.
- The merger creates another well-resourced company competing in radiopharmaceuticals, adding scale to a field long anchored by a single major player.
Why it matters: The merger instantly creates a second well-capitalized challenger to Novartis in radiopharmaceuticals, with Telix committing at least $1.65 billion upfront and up to $700 million more contingent on ITM's lead drug clearing regulatory and commercial milestones.
Ask SkimNews
